Price$2.01+0.09 (+4.69%)
01:30 PM04:30 PM
News · 26 weeks65+171%
2025-12-142026-06-07
Mix4090d
- SEC Filings18(45%)
- Other13(33%)
- Insider6(15%)
- Offering2(5%)
- Leadership1(3%)
Latest news
25 items- PRPresenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live streamMIAMI, June 10, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday June 11, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered,
- PRPresenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live streamMIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayJune 10, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to
- PRBioStem Technologies Announces Appointment of Three New Members to its Board of DirectorsPOMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors, effective as of June 5, 2026. In connection with their appointment to the Board of Directors, Mr. Sonenreich has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Committee, Ms. Hannaway has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Commit
- INSIDERDirector Tursi James Patrick was granted 17,186 shares, increasing direct ownership by 508% to 20,568 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Strickland D Gordon was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Salsbury Michael was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Groves Jason L was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Koven Andrew I was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- INSIDERDirector Glickman Mark A was granted 17,186 shares, increasing direct ownership by 499% to 20,629 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- SECSEC Form S-8 filed by MetaVia Inc.S-8 - MetaVia Inc. (0001638287) (Filer)
- SECMetaVia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- SECMetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination PotentialDA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauVanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH ModelVanoglipel Combined with Metformin Demonstrated Enhanced Glycemic Control and Body Weight Reduction Versus Monotherapy in a Preclinical T2D ModelCAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Associati
- PRMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth ConferenceCAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present an update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET. After the presentation, MetaVia's management will open the floor for questions. Attendees may submit questions in advance to questions@emerginggrowth.com, or ask questi
- SECMetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauExploratory FibroScan Assessments Demonstrated Early Liver-Related ImprovementsOngoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose LevelsCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Ass
- PRMetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASHCAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in the peer-reviewed, international journal, Biomolecules & Therapeutics. The paper, entitled, "A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic Stellate Cells," demonstrated that GPR119 agonists reduced liver fibrosi
- SECMetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific SessionsThree Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 AgonistCAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that three late-breaking abstracts highlighting its cardiometabolic assets, DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, and vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, have been accepted for poster presentations at the American Diabetes Association's (ADA) 2026 Scientific Sessions
- SECSEC Form SCHEDULE 13G filed by MetaVia Inc.SCHEDULE 13G - MetaVia Inc. (0001638287) (Subject)
- SECSEC Form 10-Q filed by MetaVia Inc.10-Q - MetaVia Inc. (0001638287) (Filer)
- SECMetaVia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step) and 64 mg (2-Step) Regimens; Data Expected in Fourth Quarter 2026CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate strategic update.
- SECMetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- PRMetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27–30, 2026 in Barcelona, Spain. "Having a late-breaking abstract on DA-1726 accepted fo
MTVA FAQ
6 questionsWhere does MTVA stock trade?
MetaVia Inc. (MTVA) is listed on NASDAQ.What sector and industry is MTVA in?
MetaVia Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MetaVia Inc. go public?
MetaVia Inc. (MTVA) completed its IPO in 2016.What are analysts saying about MTVA?
MetaVia Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-09-04. Recent price targets cluster around $1200.00.What companies are similar to MTVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MTVA side-by-side with any of them on Quantisnow.How can I track MTVA on Quantisnow?
Quantisnow aggregates MetaVia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MTVA to receive live email and push alerts on every new disclosure.